Regenerative medicine is a real field with genuine science behind it, but the gap between what’s been proven and what’s being sold to patients is enormous. The FDA has approved dozens of cellular and gene therapy products for serious conditions like cancer, genetic blood disorders, and inherited blindness. At the same time, the agency has issued explicit warnings that hundreds of clinics across the country market unapproved stem cell and exosome treatments with no proven safety or effectiveness. So the honest answer is: the science is legit, some approved treatments are legit, but many of the procedures you’ll find advertised online are not.
What Regenerative Medicine Actually Includes
Regenerative medicine is a broad category that covers any therapy designed to restore, replace, or regrow damaged tissues and organs. It pulls from engineering, biology, and clinical medicine. The strategies range from implanting lab-grown cells into injured tissue, to using gene therapy to fix a defective gene at its source, to building scaffolds that guide the body’s own repair processes. Some of these approaches have been in clinical use for years. Others are still in early research.
The confusion for consumers comes from the fact that “regenerative medicine” gets used to describe both FDA-approved gene therapies that cost hundreds of thousands of dollars and went through rigorous clinical trials, and the $1,200 platelet injection offered at a strip-mall clinic with a slick website. These are not the same thing, even though they share a label.
What the FDA Has Actually Approved
The FDA’s Office of Therapeutic Products maintains a public list of approved cellular and gene therapy products. As of 2025, that list includes roughly 50 products. Many are CAR-T cell therapies for blood cancers, where a patient’s own immune cells are reprogrammed to attack tumor cells. Others include gene therapies for inherited conditions like sickle cell disease, spinal muscular atrophy, hemophilia, and a rare form of inherited blindness. There are also approved cord blood products used for patients with blood-forming disorders, an engineered skin graft for deep burns, and a cultured cartilage product for knee repairs.
These treatments went through the full regulatory process: preclinical testing, phased clinical trials, and independent review. They represent real, validated regenerative medicine. But they’re also highly specific. Each one is approved for a particular condition, delivered in controlled medical settings, and monitored closely.
What Hasn’t Been Approved
This is where the story gets complicated. The FDA has been unusually direct in warning consumers about the vast market of unapproved regenerative treatments. The agency’s consumer alert spells it out in detail:
- Stem cell injections have not been approved for any orthopedic condition, including osteoarthritis, tendonitis, disc disease, back pain, hip pain, knee pain, or shoulder pain.
- Exosome products (tiny cell-derived particles marketed as healing agents) have zero FDA-approved versions on the market.
- No stem cell or exosome product has been approved for neurological disorders like ALS, Parkinson’s, Alzheimer’s, multiple sclerosis, or stroke.
- No approval exists for using these products to treat heart disease, lung disease, autism, macular degeneration, chronic pain, or fatigue.
That list covers nearly every condition you’ll see advertised at commercial stem cell clinics. The FDA states plainly that patients “may be misled by information about products that are illegally marketed, have not been shown to be safe or effective, and, in some cases, may have significant safety issues.”
The Problem With Stem Cell Clinics
The number of clinics offering unapproved regenerative treatments in the U.S. has grown rapidly over the past decade. Many advertise stem cell injections, platelet-rich plasma (PRP), or exosome therapy for joint pain, anti-aging, sexual wellness, and neurological conditions. They typically operate outside the clinical trial system, charge patients out of pocket, and use marketing language that implies FDA legitimacy without actually having it.
The International Society for Stem Cell Research, the leading professional body in this field, has laid out clear guidelines for distinguishing real clinical research from commercial offerings. One key distinction: when cells are substantially manipulated (extracted using enzymes, expanded in a lab, or genetically altered), their safety and effectiveness must be demonstrated through rigorous research for each specific condition. You can’t assume that because cells came from your own body, they’re safe to inject back in a different form or location. The composition changes during processing, and so do the risks.
The ISSCR also warns that patients who fund their own experimental treatments may push for study designs that skip critical safeguards like randomization and eligibility criteria. In other words, paying for an unproven treatment doesn’t make it a legitimate clinical trial. It just means you’re paying.
What the Evidence Shows for Common Treatments
Platelet-rich plasma, or PRP, is one of the most widely offered regenerative treatments. It involves drawing your blood, concentrating the platelets, and injecting them into an injured area. For knee osteoarthritis, the most-studied use case, a 2025 meta-analysis pooling data across multiple trials found a modest benefit: a small-to-moderate reduction in pain and a small improvement in function compared to control groups. The average reduction on a standard pain scale was about 8.5 points. That’s real, but it’s not dramatic, and it’s not a cure.
Bone marrow aspirate concentrate (BMAC), another common offering, has shown some promise as an add-on to surgical repair. A prospective study of 150 patients who had meniscus surgery found that those who received BMAC along with the repair experienced significantly less pain at six weeks and three months compared to surgery alone. By one year, though, both groups had improved to similar levels. The BMAC group’s average pain dropped from 5.9 to 0.7 on a 10-point scale, while the surgery-only group went from 6.1 to 1.2. Both outcomes are good. The BMAC appeared to accelerate recovery rather than improve the final result.
These findings illustrate a pattern across regenerative medicine research: some treatments show genuine but modest benefits for specific conditions, particularly when used alongside standard care. The problem isn’t that the biology is fake. It’s that the marketing often promises far more than the evidence supports.
What It Costs and Who Pays
Most unapproved regenerative treatments are not covered by insurance. PRP injections typically run $1,000 to $1,500 per injection, and patients often need multiple sessions. Total per-patient costs average around $3,000. Stem cell injections can range from $2,000 to $10,000 or more per treatment, depending on the clinic and the source of the cells.
FDA-approved regenerative therapies, by contrast, are usually covered by insurance or have manufacturer assistance programs, though their sticker prices can be staggering (some gene therapies exceed $2 million). The financial structure of the unapproved market creates a troubling incentive: clinics profit directly from selling treatments, and patients bear all the financial risk for procedures that may not work.
How to Evaluate a Clinic
If you’re considering a regenerative treatment, a few practical steps can help you separate credible options from questionable ones. First, check whether the treating physician is board certified through the American Board of Medical Specialties verification tool. Over 997,000 physicians are in their database, and the information is updated daily. Board certification doesn’t guarantee a clinic is offering proven treatments, but it confirms the physician has met peer-developed standards in their specialty.
Beyond credentials, ask specific questions. Is this treatment FDA-approved for your condition? If not, is it part of a registered clinical trial you can verify on ClinicalTrials.gov? What published evidence supports its use for your specific diagnosis? A legitimate provider will be able to point you to peer-reviewed studies rather than patient testimonials or promotional materials.
Be cautious of clinics that advertise stem cells or exosomes as treatments for a long list of unrelated conditions, charge large upfront fees, or pressure you to act quickly. The FDA encourages patients who experience adverse effects from any regenerative medicine product to report them through the MedWatch system. The fact that this reporting mechanism exists tells you something about the scale of the problem.
The Bottom Line on Legitimacy
Regenerative medicine as a scientific discipline is producing real, sometimes transformative therapies. Gene therapies are giving functional vision to children born blind. Engineered immune cells are putting aggressive cancers into remission. Lab-grown cartilage is repairing damaged knees. These are not speculative. They are approved, regulated, and backed by clinical data.
The illegitimate side of the field is the commercial market that borrows the language and excitement of this science to sell unproven treatments at premium prices. The distance between an FDA-approved gene therapy and an unapproved stem cell injection for back pain is not a matter of degree. It’s a matter of evidence, oversight, and honesty about what we know and what we don’t.